Jacob Johnson
Stock Analyst at Stephens & Co.
(2.94)
# 1,698
Out of 5,050 analysts
75
Total ratings
45.76%
Success rate
9.78%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $263.77 | -9.01% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $7.37 | -18.59% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.85 | -12.41% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $29.37 | +104.29% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $209.94 | +50.04% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $572.41 | +18.80% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $142.82 | +19.03% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.71 | +6.16% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.44 | +663.89% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $24.10 | +57.68% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $8.38 | +102.86% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.71 | +46.20% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $57.41 | +51.54% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $271.04 | +43.89% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $10.08 | +78.57% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.69 | +255.03% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $25.93 | +11.84% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $168.05 | +124.34% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $263.77
Upside: -9.01%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $7.37
Upside: -18.59%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.85
Upside: -12.41%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $29.37
Upside: +104.29%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $209.94
Upside: +50.04%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $572.41
Upside: +18.80%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $142.82
Upside: +19.03%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.71
Upside: +6.16%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.44
Upside: +663.89%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $24.10
Upside: +57.68%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $8.38
Upside: +102.86%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.71
Upside: +46.20%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $57.41
Upside: +51.54%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $271.04
Upside: +43.89%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $10.08
Upside: +78.57%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.69
Upside: +255.03%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $25.93
Upside: +11.84%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $168.05
Upside: +124.34%